Reports Q4 revenue $34.37M, consensus $24.04M. "We are proud of the significant progress advancing our clinical pipeline in 2022 and excited and well-prepared to deliver results from five pivotal phase 3 trials in 2023," said Enrique Conterno, Chief Executive Officer, FibroGen. "FibroGen represents a catalyst-rich opportunity with each of these trials representing an opportunity to provide a novel treatment to address a significant unmet medical need."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FGEN:
- FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
- FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
- FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
- FibroGen to Present at SVB Securities Global Biopharma Conference
- FibroGen upgraded to Outperform at William Blair on pamrevlumab’s potential
